Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
licensor Processed

BioArctic & Eisai

15 shared events · Importance 6 · Last updated Sep 01, 2026

Importance
6
Shared Events
15
Actions
2
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard

BioArctic is a research-based biopharma company that licenses its proprietary technologies and drug candidates, including Leqembi and BrainTransporter, to Eisai for global development and commercialization of Alzheimer's treatments.

100
Regulatory
BioArctic: BioArctic is the inventor of Leqembi and receives royalties on global sales. The Canadian reimbursement recommendation is a positive development that could increase future revenue.
Eisai: Eisai is the global commercialization partner for Leqembi. The recommendation supports broader market access in Canada, potentially increasing sales and revenue.
Sep 01, 2026 · 6 articles
95
Business
BioArctic: BioArctic receives royalties from Leqembi sales; Q2 2026 royalty of SEK 179 million represents 10% growth, boosting revenue outlook.
Eisai: Eisai reported Leqembi sales of JPY 29.3 billion in Q2 2026, driving its revenue and partnership with Biogen.
Jul 29, 2026 · 6 articles
95
Business
BioArctic: Inventor of lecanemab; entitled to royalties and sales milestones from Eisai. The US launch of Leqembi Iqlik strengthens its commercial prospects.
Eisai: Partner responsible for development and commercialization; launched Leqembi Iqlik in the US, expanding its Alzheimer's franchise.
Aug 24, 2026 · 6 articles
92
Business
BioArctic: As the inventor of Lecanemab and a partner in its development and commercialization, BioArctic stands to benefit significantly from the projected sales, receiving royalties and milestone payments. This event positively impacts its financial outlook.
Eisai: Eisai, as the primary developer and commercializer of Lecanemab, presented the sales simulation, indicating strong future revenue growth for the company. This positively impacts its financial projections and market position.
May 25, 2026 · 7 articles
82
Tech
BioArctic: BioArctic is the central actor, announcing the first Swedish patient treated with Leqembi and holding Nordic commercialization rights with Eisai. The launch supports its royalty and milestone revenue stream, though the negative NT-radet reimbursement recommendation limits near-term Swedish sales.
Eisai: Eisai leads global clinical development and commercialization of Leqembi and worked with BioArctic to enable Swedish patient access. The Swedish launch adds incremental commercial reach in the Nordics.
Sep 22, 2026 · 7 articles
32
Business
BioArctic: BioArctic held its Annual General Meeting, making several key resolutions including dividend payment, board re-elections, and approval of an incentive program, which directly impacts its corporate governance and shareholder value.
Eisai: Eisai is BioArctic's partner for Leqembi, responsible for regulatory interactions and commercialization globally, indicating a significant collaboration for BioArctic's key product.
May 28, 2026 · 9 articles
32
Business
BioArctic: BioArctic issued 5,000 Class B shares to participants in its stock option program, increasing its total number of shares and votes.
Eisai: Eisai is mentioned as BioArctic's partner in developing and commercializing Leqembi.
May 29, 2026 · 6 articles
32
Business
BioArctic: BioArctic is the company issuing the Q2 report and hosting the investor presentation. The event is routine and does not change its outlook.
Eisai: Eisai is BioArctic's partner for Leqembi commercialization. The Q2 report may include updates on Leqembi sales, but no specific impact is announced.
Aug 19, 2026 · 6 articles
32
Business
BioArctic: BioArctic is a key party, contributing its BrainTransporter technology and leading drug candidate generation. The collaboration expands its pipeline into oncology, potentially enhancing its growth prospects.
Eisai: Eisai is BioArctic's partner for Leqembi, but is not directly involved in this collaboration. The event does not materially affect Eisai.
Aug 19, 2026 · 6 articles
32
Business
BioArctic: BioArctic issued 20,200 Class B shares under its stock option program, increasing its total share count to 88,744,685. This routine action has no significant impact on the company's valuation or operations.
Eisai: Eisai is BioArctic's partner for Leqembi, but this share issuance does not affect Eisai directly. The event is unrelated to their collaboration.
Aug 31, 2026 · 8 articles
20
Tech
BioArctic: Greta Duréel has consulted for BioArctic, but no direct impact from this study.
Eisai: Greta Duréel has consulted for Eisai, but no direct impact from this study.
Aug 12, 2026 · 14 articles
0
Business
BioArctic: BioArctic, in collaboration with Eisai, developed Lecanemab and is set to receive approximately SEK 880 million in royalties from the projected sales, indicating a positive financial outlook for the company.
May 15, 2026 · 6 articles
0
Business
May 13, 2026 · 7 articles
0
Regulatory
May 08, 2026 · 14 articles
0
Business
Apr 21, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how BioArctic and Eisai interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.